

Menggang Yu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6178111/menggang-yu-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

3,752
citations

32
h-index

59
g-index

135
ext. papers

4,649
ext. citations

5.8
avg, IF

5.02
L-index

#	Paper	IF	Citations
123	Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. <i>Annals of Internal Medicine</i> , 2014 , 161, 765-74	8	425
122	NF1-dependent tumors require a microenvironment containing NF1+/- and c-kit-dependent bone marrow. <i>Cell</i> , 2008 , 135, 437-48	56.2	276
121	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1218-24	21.7	168
120	CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. <i>Cancer Cell</i> , 2014 , 25, 21-36	24.3	159
119	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4416-26	2.2	152
118	Advanced cognitive training for breast cancer survivors: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 799-809	4.4	139
117	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017 , 3, 1663-1672	13.4	138
116	Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. <i>Blood</i> , 2005 , 105, 3737-42	2.2	126
115	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology, The</i> , 2016 , 17, 1612-1620	21.7	124
114	Prevalence of Human Papillomavirus in Oropharyngeal Cancer: A Systematic Review. <i>Cancer Journal (Sudbury, Mass)</i> , 2015 , 21, 138-46	2.2	105
113	Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. <i>Human Molecular Genetics</i> , 2006 , 15, 2837-45	5.6	75
112	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 175-81	3.3	74
111	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. <i>Clinical Cancer Research</i> , 2013 , 19, 855-64	12.9	72
110	Prevalence of human papillomavirus in oropharyngeal squamous cell carcinoma in the United States across time. <i>Chemical Research in Toxicology</i> , 2014 , 27, 462-9	4	68
109	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018 , 73, 751-759	10.2	67
108	Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. <i>Breast Cancer Research</i> , 2017 , 19, 9	8.3	64
107	Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival Cure Model. <i>Journal of the American Statistical Association</i> , 2008 , 103, 178-187	2.8	62

106	NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. <i>Cancer Letters</i> , 2009 , 278, 145-155	9.9	60
105	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1797-1806	2.2	56
104	Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. <i>Oncologist</i> , 2012 , 17, 13	5.7	53
103	A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 460-5	2.7	52
102	Bias and Efficiency Loss Due to Categorizing an Explanatory Variable. <i>Journal of Multivariate Analysis</i> , 2002 , 83, 248-263	1.4	50
101	Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 985-993	4	48
100	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2012 , 38, 919-25	14.4	45
99	A general statistical framework for subgroup identification and comparative treatment scoring. <i>Biometrics</i> , 2017 , 73, 1199-1209	1.8	42
98	The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. <i>American Journal of Pathology</i> , 2018 , 188, 559-573	5.8	42
97	Ethanol-induced alterations in fatty acid-related lipids in serum and tissues in mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2011 , 35, 229-34	3.7	42
96	Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. <i>Gastrointestinal Endoscopy</i> , 2010 , 71, 260-5	5.2	41
95	Regularized outcome weighted subgroup identification for differential treatment effects. <i>Biometrics</i> , 2015 , 71, 645-53	1.8	37
94	Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2008-11	8.9	35
93	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer. <i>Urology</i> , 2002 , 60, 276-80	1.6	35
92	Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. <i>Journal of General Internal Medicine</i> , 2013 , 28, 193-200	4	33
91	Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology. <i>JAMA Network Open</i> , 2020 , 3, e207559	10.4	29
90	Risk factors, pathophysiology, and treatment of hot flashes in cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2013 , 63, 167-92	220.7	28
89	Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants. <i>Molecular and Cellular Biology</i> , 2009 , 29, 4376-93	4.8	28

88	Censored linear regression for case-cohort studies. <i>Biometrika</i> , 2006 , 93, 747-762	2	28
87	Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 93-6	8.9	26
86	A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. <i>Investigational New Drugs</i> , 2013 , 31, 1307-10	4.3	25
85	Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017 , 143, 2341-2350	4.9	24
84	Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21 Suppl 2, 60-8	2.6	22
83	Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables. <i>Statistics in Medicine</i> , 2016 , 35, 4837-4855	2.3	20
82	Meta-analysis based variable selection for gene expression data. <i>Biometrics</i> , 2014 , 70, 872-80	1.8	20
81	Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. <i>Pediatric Research</i> , 2009 , 65, 613-8	3.2	20
80	Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 374-9	8.9	19
79	On the effect of electronic patient portal on primary care utilization and appointment adherence. <i>BMC Medical Informatics and Decision Making</i> , 2018 , 18, 84	3.6	19
78	A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 86-97	2.6	17
77	Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1420-4	8.9	17
76	Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	16
75	Genetic disruption of the PI3K regulatory subunits, p85 and p55 and p50 normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. <i>Haematologica</i> , 2012 , 97, 1042-7	6.6	16
74	A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naïve malignancies. <i>Clinical Cancer Research</i> , 2008 , 14, 1131-7	12.9	16
73	Drug-drug interaction prediction: a Bayesian meta-analysis approach. <i>Statistics in Medicine</i> , 2007 , 26, 3700-21	2.3	16
72	Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017 , 143, 1126-1133	3.9	15
71	Prediction of coronary artery disease risk based on multiple longitudinal biomarkers. <i>Statistics in Medicine</i> , 2016 , 35, 1299-314	2.3	15

70	Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression. <i>Metabolomics</i> , 2013 , 9, 202-212	4.7	15
69	A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. <i>Investigational New Drugs</i> , 2009 , 27, 565-70	4.3	15
68	Chemoprotective Effects of Dietary Grape Powder on UVB Radiation-Mediated Skin Carcinogenesis in SKH-1 Hairless Mice. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 552-561	4.3	15
67	A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1425-9	8.9	14
66	Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). <i>Journal of Clinical Oncology</i> , 2018 , 36, 975-980	2.2	14
65	Hospice Enrollment, Local Hospice Utilization Patterns, and Rehospitalization in Medicare Patients. <i>Journal of Palliative Medicine</i> , 2015 , 18, 601-12	2.2	13
64	Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 25-32	3.5	13
63	A hybrid Newton-type method for censored survival data using double weights in linear models. <i>Lifetime Data Analysis</i> , 2006 , 12, 345-64	1.3	12
62	Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. <i>Head and Neck</i> , 2017 , 39, 2159-2170	4.2	11
61	Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. <i>Clinical Lung Cancer</i> , 2013 , 14, 224-9	4.9	10
60	Stat3 downstream gene product chitinase 3-like 1 is a potential biomarker of inflammation-induced lung cancer in multiple mouse lung tumor models and humans. <i>PLoS ONE</i> , 2013 , 8, e61984	3.7	10
59	Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. <i>Menopause</i> , 2009 , 16, 644-52	2.5	10
58	Semiparametric regression on cumulative incidence function with interval-censored competing risks data. <i>Statistics in Medicine</i> , 2017 , 36, 3683-3707	2.3	9
57	Somatosensory amplification and menopausal symptoms in breast cancer survivors and midlife women. <i>Maturitas</i> , 2014 , 78, 51-5	5	9
56	Bayesian approach for flexible modeling of semicompeting risks data. <i>Statistics in Medicine</i> , 2014 , 33, 5111-25	2.3	9
55	Strategies used and data obtained during treatment fidelity monitoring. <i>Nursing Research</i> , 2013 , 62, 59-65	1.9	9
54	Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs. <i>BMC Medical Research Methodology</i> , 2015 , 15, 48	4.7	8
53	Regression calibration in semiparametric accelerated failure time models. <i>Biometrics</i> , 2010 , 66, 405-14	1.8	8

52	Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. <i>Cancer Nursing</i> , 2012 , 35, 195-202	2.6	8
51	A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction. <i>Journal of Biopharmaceutical Statistics</i> , 2008 , 18, 1063-83	1.3	8
50	Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 662-667	2.7	8
49	Thirty-Day Re-observation, Chronic Re-observation, and Neighborhood Disadvantage. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2644-2654	6.4	7
48	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019 , 21, 1141-1149	1.9	6
47	Group variable selection via convex log-exp-sum penalty with application to a breast cancer survivor study. <i>Biometrics</i> , 2015 , 71, 53-62	1.8	6
46	HPV impacts survival of stage IVC non-orpharyngeal HNSCC cancer patients 2018 , 3,		6
45	Joint Models for Multiple Longitudinal Processes and Time-to-event Outcome. <i>Journal of Statistical Computation and Simulation</i> , 2016 , 86, 3682-3700	0.9	6
44	Optimal treatment assignment to maximize expected outcome with multiple treatments. <i>Biometrics</i> , 2018 , 74, 506-516	1.8	6
43	A Computational-Based Approach to Identify Estrogen Receptor / Heterodimer Selective Ligands. <i>Molecular Pharmacology</i> , 2018 , 93, 197-207	4.3	5
42	Risk prediction for heterogeneous populations with application to hospital admission prediction. <i>Biometrics</i> , 2018 , 74, 557-565	1.8	5
41	A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect. <i>Biometrics</i> , 2018 , 74, 1292-1300	1.8	5
40	Sample size under the additive hazards model. <i>Clinical Trials</i> , 2016 , 13, 188-98	2.2	4
39	The importance of health insurance claims data in creating learning health systems: evaluating care for high-need high-cost patients using the National Patient-Centered Clinical Research Network (PCORNet). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 1305-1313	8.6	4
38	Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors. <i>PLoS ONE</i> , 2015 , 10, e0128143	3.7	4
37	Buckley-James Type Estimator for Censored Data with Covariates Missing by Design. <i>Scandinavian Journal of Statistics</i> , 2011 , 38, 252-267	0.8	4
36	Buckley-James-type of estimators under the classical case cohort design. <i>Annals of the Institute of Statistical Mathematics</i> , 2007 , 59, 675-695	1	4
35	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. <i>Neurology</i> , 2021 , 96, e2500-e2512	6.5	4

34	A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). <i>Annals of Surgical Oncology</i> , 2018 , 25, 2587-2595	3.1	4
33	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). <i>Journal of Geriatric Oncology</i> , 2014 , 5, 230-7	3.6	3
32	Evaluating the role of serotonin on neuropsychological function after breast cancer using acute tryptophan depletion. <i>Biological Research for Nursing</i> , 2012 , 14, 5-15	2.6	3
31	A practical model for research with learning health systems: Building and implementing effective complex case management. <i>Applied Ergonomics</i> , 2020 , 84, 103023	4.2	3
30	A Semiparametric Approach to Model Effect Modification. <i>Journal of the American Statistical Association</i> , 2020 , 1-13	2.8	3
29	Improving estimation efficiency for semi-competing risks data with partially observed terminal event. <i>Journal of Nonparametric Statistics</i> , 2016 , 28, 860-874	0.7	3
28	Utility of Clinical Breast Examinations in Detecting Local-Regional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3385-91	3.1	3
27	Impact of sufficient dimension reduction in nonparametric estimation of causal effect. <i>Statistical Theory and Related Fields</i> , 2018 , 2, 89-95	0.3	3
26	A new method to address unmeasured confounding of mortality in observational studies. <i>Learning Health Systems</i> , 2017 , 1, e10016	3	2
25	Marginal and Conditional Distribution Estimation from Double-Sampled Semi-Competing Risks Data. <i>Scandinavian Journal of Statistics</i> , 2015 , 42, 87-103	0.8	2
24	Advanced colorectal neoplasia risk stratification by penalized logistic regression. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 1677-91	2.3	2
23	One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 477-485	5.3	2
22	Instrumental variable based estimation under the semiparametric accelerated failure time model. <i>Biometrics</i> , 2019 , 75, 516-527	1.8	2
21	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021 , 7, 1644-1652	13.4	2
20	Fused comparative intervention scoring for heterogeneity of longitudinal intervention effects. <i>Annals of Applied Statistics</i> , 2019 , 13,	2.1	1
19	Treatment recommendation and parameter estimation under single-index contrast function. <i>Statistical Theory and Related Fields</i> , 2017 , 1, 171-181	0.3	1
18	Designing cost-efficient randomized trials by using flexible recruitment strategies. <i>BMC Medical Research Methodology</i> , 2012 , 12, 106	4.7	1
17	Testing and Sample Size for Polygonal One-Sided Hypotheses on Bivariate Binary Outcomes. <i>Statistics in Biopharmaceutical Research</i> , 2013 , 5, 1-17	1.2	1

16	Quantile treatment effect estimation with dimension reduction. <i>Statistical Theory and Related Fields</i> , 2020 , 4, 202-213	0.3	1
15	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. <i>Hematological Oncology</i> , 2021 , 39, 473-482	1.3	1
14	A Statistical Framework for Pathway and Gene Identification from Integrative Analysis. <i>Journal of Multivariate Analysis</i> , 2017 , 156, 1-17	1.4	0
13	Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints. <i>Statistics in Biopharmaceutical Research</i> , 2019 , 11, 274-282	1.2	0
12	Tailored interventions to reduce hospital admissions for individuals with cerebral palsy. <i>Developmental Medicine and Child Neurology</i> , 2020 , 62, 889	3.3	0
11	Cox regression with survival-time-dependent missing covariate values. <i>Biometrics</i> , 2020 , 76, 460-471	1.8	0
10	Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer.. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022 , 45, 202-207	2.7	0
9	Sample Size Determination for Stratified Phase II Cancer Trials With Monotone Order Constraints. <i>Statistics in Biopharmaceutical Research</i> , 2020 , 1-10	1.2	
8	Personalised treatment assignment maximising expected benefit with smooth hinge loss. <i>Statistical Theory and Related Fields</i> , 2017 , 1, 37-47	0.3	
7	Discussion of "Combining biomarkers to optimize patient treatment recommendations" by Chaeryon Kang, Holly Janes, and Ying Huang. <i>Biometrics</i> , 2014 , 70, 716-9	1.8	
6	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. <i>Statistics and Its Interface</i> , 2019 , 12, 355-363	0.4	
5	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. <i>Statistics and Its Interface</i> , 2019 , 12, 355-363	0.4	
4	Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG). <i>Blood</i> , 2010 , 116, 2780-2780	2.2	
3	The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells.. <i>Blood</i> , 2012 , 120, 2420-2420	2.2	
2	Tailored optimal posttreatment surveillance for cancer recurrence. <i>Biometrics</i> , 2021 , 77, 942-955	1.8	
1	Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.. <i>Cureus</i> , 2022 , 14, e23783	1.2	